Corsair Pharma Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$23M
- Investors
-
6
Corsair Pharma General Information
Description
Developer of novel treprostinil drugs designed to improve the therapeutic profile of medications and provide superior treatment options for patients. The company focuses on delivering an inactive prodrug of treprostinil, which is designed to cross the skin, enter the blood, and convert rapidly to treprostinil in the liver, that has the potential to offer efficacy and fast titration of parenteral delivery, enabling healthcare professionals to treat patients using a once-daily transdermal patch.
Contact Information
Website
www.corsairpharma.comCorporate Office
- 5600 Mowry School Road
- Suite 330
- Newark, CA 94560
- United States
Corporate Office
- 5600 Mowry School Road
- Suite 330
- Newark, CA 94560
- United States
Corsair Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series B) | 20-Sep-2023 | $23M | Completed | Clinical Trials - Phase 1 | ||
| 1. Secondary Transaction - Private | 04-Jan-2018 | Completed | Clinical Trials - Phase 1 |
Corsair Pharma Comparisons
Industry
Financing
Details
Corsair Pharma Competitors (4)
One of Corsair Pharma’s 4 competitors is Galectin Therapeutics, a Corporation company based in Norcross, GA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Galectin Therapeutics | Corporation | Norcross, GA | ||||
| APT Therapeutics | Venture Capital-Backed | Saint Louis, MO | ||||
| Gossamer Bio | Formerly VC-backed | San Diego, CA | ||||
| Peloton Therapeutics | Formerly VC-backed | Dallas, TX |
Corsair Pharma Signals
Corsair Pharma Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Junson Capital | Asset Manager | Minority | ||
| Midas Capital Partners | Corporation | Minority | ||
| New Rhein Healthcare | Venture Capital | Minority | ||
| Plaisance Capital Management | Venture Capital | Minority | ||
| Primavera Capital Group | Growth/Expansion | Minority |
Corsair Pharma FAQs
-
When was Corsair Pharma founded?
Corsair Pharma was founded in 2014.
-
Where is Corsair Pharma headquartered?
Corsair Pharma is headquartered in Newark, CA.
-
What is the size of Corsair Pharma?
Corsair Pharma has 5 total employees.
-
What industry is Corsair Pharma in?
Corsair Pharma’s primary industry is Drug Discovery.
-
Is Corsair Pharma a private or public company?
Corsair Pharma is a Private company.
-
What is Corsair Pharma’s current revenue?
The current revenue for Corsair Pharma is .
-
How much funding has Corsair Pharma raised over time?
Corsair Pharma has raised $23M.
-
Who are Corsair Pharma’s investors?
Junson Capital, Midas Capital Partners, New Rhein Healthcare, Plaisance Capital Management, and Primavera Capital Group are 5 of 6 investors who have invested in Corsair Pharma.
-
Who are Corsair Pharma’s competitors?
Galectin Therapeutics, APT Therapeutics, Gossamer Bio, and Peloton Therapeutics are competitors of Corsair Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process